# Becton Dickinson & Co: Form 10-Q for the period ended Dec 31, 2010

- Company: [Becton Dickinson & Co](/companies/bdx.md) (CIK 10795)
- Form: 10-Q
- Filed: 2011-02-08
- Accepted by EDGAR: Feb 8, 2011, 17:12 ET
- Period: 2010-12-31
- Accession: 0000950123-11-010361
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/10795/000095012311010361/y89077e10vq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/10795/000095012311010361/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2010-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2010-10-01 to 2010-12-31 | $1.84bn | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2010-10-01 to 2010-12-31 | $865.4m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2010-10-01 to 2010-12-31 | $448.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2010-10-01 to 2010-12-31 | $413.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2010-10-01 to 2010-12-31 | $15.6m | us-gaap:InterestExpense |
| Income tax | 3 months, 2010-10-01 to 2010-12-31 | $93.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2010-10-01 to 2010-12-31 | $315.9m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2010-10-01 to 2010-12-31 | $1.36 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2010-10-01 to 2010-12-31 | $1.39 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2010-10-01 to 2010-12-31 | 232,915,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2010-10-01 to 2010-12-31 | $469.7m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 3 months, 2010-10-01 to 2010-12-31 | $79.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2010-10-01 to 2010-12-31 | $92.7m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months, 2010-10-01 to 2010-12-31 | $836.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2010-12-31 | $1.25bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2010-12-31 | $4.95bn | us-gaap:AssetsCurrent |
| Total assets | at 2010-12-31 | $10.07bn | us-gaap:Assets |
| Current liabilities | at 2010-12-31 | $1.61bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | at 2010-12-31 | $235.3m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2010-12-31 | $4.88bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2010-12-31 | 221,114,838 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 32,199 characters.

#### Company Overview

Becton, Dickinson and Company (“BD”) is a global medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Our business consists of three worldwide business segments — BD Medical (“Medical”), BD Diagnostics (“Diagnostics”) and BD Biosciences (“Biosciences”). Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives.

#### Overview of Financial Results

First quarter revenues of $1.842 billion represented a decrease of 1.4% from the same period a year ago. Substantially all of this decline is due to volume decreases. Foreign exchange and price changes had a minimal impact on revenue growth in first quarter of 2011. First quarter revenue growth reflected an unfavorable comparison to the prior year’s quarter that included strong flu pandemic-related sales and U.S. stimulus orders. This unfavorable comparison lowered revenue growth for the quarter by approximately 4 percentage points. Sales in the United States of safety-engineered devices in the first quarter of 2011 were $284 million, representing a 3% decrease from the prior year’s period. First quarter U.S. safety revenue growth was unfavorably impacted by the aforementioned unfavorable comparison resulting from the strong flu pandemic-related sales in the prior year’s quarter. This unfavorable comparison lowered revenue growth in U.S. safety-engineered devices by approximately 9 percentage points. International sales of safety-engineered devices of $169 million in the first quarter of 2011 grew 9% above such sales in the prior year’s period, including an estimated $2 million, or 2%, favorable impact due to foreign currency translation. First quarter international safety revenue growth was negatively impacted by about 2 percentage points by the unfavorable comparison resulting from the strong flu pandemic-related sales in the prior year’s quarter.

Our financial condition continues to remain strong, with cash flows from continuing operating activities totaling $470 million in the first quarter of 2011. In November 2010, we issued $700 million of 10-year 3.25% notes and $300 million of 30-year 5.00% notes, as discussed further below. We continued to return value to our shareholders as we repurchased $837 million of our common stock and paid cash dividends of $93 million in the first quarter of 2011.

We face currency exposure each reporting period that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that fluctuate from the beginning of such period. From time to time, we purchase forward contracts and options to partially protect against adverse foreign exchange rate movements. Gains or losses on our derivative instruments are largely offset by the gains or losses on the underlying hedged transactions. We do not enter into derivative instruments for trading or speculative purposes. As of December 31, 2010, we had not entered into contracts to hedge cash flows in fiscal year 2011. During the first quarter of 2011, revenues were unfavorably impacted by foreign translation currency due to the strengthening of the U.S. dollar against the Euro, partially offset by the weakening of the U.S. dollar against other currencies such as the Japanese Yen and Asia-Pacific currencies. The net unfavorable impact of foreign currency translation in the first quarter of 2011 substantially offset the favorable comparison of hedge losses recognized in the prior year’s quarter. For further discussion refer to Note 11 in the Notes to Condensed Consolidated Financial Statements.

The recently-enacted U.S. healthcare reform legislation contains certain tax provisions that will affect BD. The most significant impact is the medical device excise tax which imposes a 2.3% tax on certain U.S. sales of medical devices, beginning in January 2013. Sales of BD products that we estimate to be subject to this tax represented approximately 80% of BD’s total U.S. revenues in fiscal year 2010.

#### Results of Operations

#### Revenues

Refer to Note 6 in the Notes to Condensed Consolidated Financial Statements for segment financial data.

#### Medical Segment

First quarter revenues of $927 million represented a decrease of $44 million, or 4.5%, compared with the prior year’s quarter, including an estimated $2 million, or 0.2%, unfavorable impact due to foreign currency translation.

The following is a summary of first quarter Medical revenues by organizational unit:

| (millions of dollars) | Three months ended December 31, 2010 | 2009 | Total Change | Estimated Foreign Exchange Impact |
| --- | ---: | ---: | ---: | ---: |
| Medical Surgical Systems | $513 | $533 | (3.8%) | 0.9% |
| Diabetes Care | 214 | 202 | 6.1% | — |
| Pharmaceutical Systems | 200 | 236 | (15.3%) | (2.9%) |
| Total Revenues | $927 | $971 | (4.5%) | (0.2%) |

Medical revenue growth in the segment reflected an unfavorable comparison to the prior year period that included sales related to the H1N1 flu pandemic. This unfavorable comparison lowered Medical’s revenue growth by approximately 6 percentage points. Revenue growth in Diabetes Care products was primarily driven by continued strong sales of pen needles. This growth was more than offset by an unfavorable comparison of Pharmaceutical Systems first quarter revenues versus the prior-year period caused by strong sales from the H1N1 flu pandemic and the timing of certain orders in 2010. Global sales of safety-engineered products were $213 million, as compared with $221 million in the prior year’s quarter, and included an estimated $1 million favorable impact due to foreign currency translation.

Medical operating income for the first quarter was $276 million, or 29.7% of Medical revenues, compared with $303 million, or 31.2% of segment revenues, in the prior year’s quarter. Gross profit margin was slightly higher in the current quarter than the first quarter of 2010 due to relatively higher sales of products with higher gross margins and continued strength in manufacturing productivity, as well as favorable foreign currency translation. These favorable impacts on gross profit margin were partially offset by increases in certain raw material costs, higher pension costs allocated to the segment, higher manufacturing start-up costs as well as costs incurred related to the segment’s low-cost sustainability program. See further discussion on gross profit margin below. Selling and administrative expense as a percent of Medical revenues in the first quarter of 2011 was higher than the comparable amount in the first quarter of 2010, as the impact of favorable foreign currency translation was more than offset by higher pension costs. Research and development expenses for the quarter increased $5 million, or 17%, above the prior year’s period, reflecting increased investment in new products and platforms.

#### Diagnostics Segment

First quarter revenues of $602 million represented an increase of $6 million, or 1%, over the prior year’s quarter, including an estimated $2 million, or 0.4%, favorable impact due to foreign currency translation.

The following is a summary of first quarter Diagnostics revenues by organizational unit:

| (millions of dollars) | Three months ended December 31, 2010 | 2009 | Total Change | Estimated Foreign Exchange Impact |
| --- | ---: | ---: | ---: | ---: |
| Preanalytical Systems | $313 | $300 | 4.2% | 0.3% |
| Diagnostic Systems | 289 | 295 | (2.1%) | 0.5% |
| Total Revenues | $602 | $595 | 1.0% | 0.4% |

Diagnostics segment growth reflected an unfavorable comparison to the prior year period that included strong sales related to the flu pandemic. This unfavorable comparison lowered Diagnostics’ revenue growth by approximately 2 percentage points. Segment revenue growth was primarily driven by solid growth in Preanalytical Systems safety-engineered products and Women’s Health and Cancer products in the Diagnostic Systems unit. Global sales of safety-engineered products in the Preanalytical Systems unit in the first quarter totaled $240 million, compared with $226 million in the prior year’s quarter, and included an estimated $1 million favorable impact due to foreign currency translation.

Diagnostics operating income for the first quarter was $161 million, or 26.8% of Diagnostics revenues, compared with $162 million, or 27.3% of segment revenues, in the prior year’s quarter. Gross profit margin was slightly higher in the current quarter than in the prior year’s quarter primarily due to relatively higher sales of products with higher gross margins, lower manufacturing start-up costs and favorable foreign currency translation. These favorable impacts on gross profit margin were partially offset by increases in certain raw material costs and higher pension costs. See further discussion on gross profit margin below. Selling and administrative expense as a percentage of Diagnostics revenues in the first quarter of 2011 was flat compared with the prior year’s period. Research and development expenses in the first quarter of 2011 increased $5 million, or 14% compared with the prior year’s period, reflecting increased investment in new products and platforms.

#### Biosciences Segment

First quarter revenues of $314 million represented an increase of $11 million, or 3.7%, over the prior year’s quarter, including an estimated $1 million, or 0.2%, favorable impact due to foreign currency translation.

The following is a summary of first quarter Biosciences revenues by organizational unit:

| (millions of dollars) | Three months ended December 31, 2010 | 2009 | Total Change | Estimated Foreign Exchange Impact |
| --- | ---: | ---: | ---: | ---: |
| Cell Analysis | $241 | $231 | 4.1% | (0.1%) |
| Discovery Labware | 73 | 71 | 2.3% | 1.1% |
| Total Revenues \* | $314 | $303 | 3.7% | 0.2% |

\* Amounts may not add due to rounding

Biosciences segment revenue growth reflected an unfavorable comparison to the prior year’s period that included strong sales from U.S. stimulus spending. This unfavorable comparison lowered Biosciences’ revenue growth by approximately 2 percentage points. Revenue growth was primarily driven by Cell Analysis instrument and reagent sales and Advanced Bioprocessing product sales in the Discovery Labware unit.

Biosciences operating income for the first quarter was $90 million, or 28.8% of Biosciences revenues, compared with $85 million, or 28.2% of segment revenues, in the prior year’s quarter. Gross profit margin was higher in the current quarter than the first quarter of 2010, reflecting relatively higher sales of products and services with higher gross margins, favorable manufacturing variances due to efficiency gains and favorable manufacturing costs. These favorable variances from the prior year’s period were partially offset by the increases in certain raw material costs, higher pension costs allocated to the segment and higher manufacturing start-up costs. See further discussion on gross profit margin below. Selling and administrative expense as a percent of Biosciences revenues for the quarter was lower compared with the prior year’s quarter, due to continued spending controls and favorable foreign currency translation. Research and development spending in the quarter increased $5 million, or 25% above the prior-year period, due to new product programs.

#### Geographic Revenues

Revenues in the United States for the first quarter of $829 million represented a decrease of $25 million, or 3%, compared with the prior year’s quarter. U.S. revenue growth rates for the Medical and Diagnostics segments in the U.S. reflected the unfavorable comparison resulting from flu pandemic-related sales in the prior year’s period, as previously discussed. Biosciences segment revenues in the U.S. reflected strong growth of instrument and reagent sales in the Cell Analysis unit, offset by the unfavorable comparison caused by the impact of U.S. stimulus-related orders in the prior year’s period. International revenues for the first quarter of $1.013 billion represented a decrease of $2 million, or 0.2%, over the prior year’s quarter, including an estimated $1 million, or 0.1%, favorable impact due to foreign currency translation. International revenues for the Medical and Diagnostics segments reflected the unfavorable comparison due to flu pandemic-related sales in the prior year’s period, offset by strong growth in emerging markets, including China and Latin America. Biosciences segment international revenue growth reflected increased instrument and reagent sales in Asia-Pacific and Latin America.

#### Gross Profit Margin

Gross profit margin was 53.0% for the first quarter, compared with 52.1% for the comparable prior-year period. Gross profit margin in the first quarter of 2011 as compared with the prior year’s period reflected an estimated favorable impact of 70 basis points from both foreign currency translation and the hedging of certain foreign currencies, in particular the Euro, as previously discussed above under “Overview of Financial Results.” Operating performance favorably impacted gross margin by 20 basis points compared with prior year. This resulted from increased sales of products with relatively higher gross margins and increased productivity, which were partially offset by increases in certain raw material costs, higher pension costs, higher manufacturing start-up costs as well as costs incurred related to the Medical segment’s low-cost sustainability program.

#### Selling and Administrative Expense

Selling and administrative expense was 24.3% of revenues for the first quarter, compared with 23.8% in the prior year’s period. Aggregate expenses for the first quarter reflected increased pension costs of $4 million and a $3 million increase in the deferred compensation liability, as further discussed below. Aggregate expenses also included $1 million related to our global enterprise resource planning initiative to update our business information systems. These increases were offset by a decrease in core spending of $4 million compared with the prior year’s period, as well as a favorable foreign exchange impact of $2 million.

#### Research and Development Expense

Research and development expense was $116 million, or 6.3% of revenues, for the first quarter, an increase of 17% compared with the prior year’s amount of $99 million, or 5.3% of revenues, reflecting increased spending for key programs in each of our segments.

#### Non-Operating Expense and Income

Interest income was $15 million in the first quarter compared with $9 million in the prior year’s period. The current quarter’s increase reflected the impact of higher investment levels as well as investment gains on assets related to our deferred compensation plan. The related increase in the deferred compensation plan liability was recorded as an increase in selling and administrative expenses. Interest expense was $16 million in the first quarter, compared with $13 million in the prior year’s period. This increase reflects higher levels of long-term fixed rate debt, partially offset by a benefit from higher levels of capitalized interest.

#### Income Taxes

The income tax rate was 23.0% for the first quarter, compared with the prior year’s rate of 28.1%. The decrease in the income tax rate in the first quarter compared with the prior year period’s rate reflected the favorable impact due to the timing of certain tax benefits. These benefits resulted from the retroactive extension of the U.S. research tax credit as well as a European restructuring transaction, both of which occurred in the first quarter of 2011.

#### Income from Continuing Operations and Diluted Earnings Per Share from Continuing Operations

Income from continuing operations and diluted earnings per share from continuing operations for the first quarter of 2011 were $314 million and $1.35, respectively. Income from continuing operations and diluted earnings per share from continuing operations for the prior year’s first quarter were $304 million and $1.25, respectively. The current quarter’s earnings reflected an estimated $0.04 overall net favorable impact of foreign exchange fluctuations.

#### Liquidity and Capital Resources

Cash generated from operations, along with available cash and cash equivalents, including proceeds from the first quarter debt issuance as further discussed below, is expected to be sufficient to fund our normal operating needs. Normal operating needs in fiscal year 2011 include capital expenditures, cash dividends and common stock repurchases. Net cash provided by continuing operating activities was $470 million during the first quarter of 2011, compared with $371 million in the same period in 2010. The current period change in operating assets and liabilities was a net use of cash and reflected higher inventory levels. Net cash provided by continuing operating activities in the first quarter 2010 was reduced by changes in the pension obligation resulting partially from discretionary cash contributions of approximately $175 million.

Net cash used for continuing investing activities for the first quarter of the current year was $567 million, compared with $141 million in the prior-year period. The increase in cash used for purchases of investments in the first quarter of 2011 reflected the extension of maturities of certain highly liquid investments beyond three months. Capital expenditures were $80 million in the first quarter of 2011 and $111 million in the same period in 2010. The prior year amount reflected the payment of $275 million of net cash relating to the HandyLab acquisition in the first quarter of fiscal year 2010.

On February 4, 2011, BD signed a definitive agreement to acquire Accuri Cytometers, Inc., an Ann Arbor, Michigan-based company that develops and manufactures personal flow cytometers for researchers. The acquisition is subject to regulatory approvals and is expected to close during the third quarter of fiscal year 2011.

Net cash provided by continuing financing activities for the first quarter of the current year was $136 million, compared with net cash used for continuing financing activities of $467 million in the prior-year period. For the first quarter of the current year, we repurchased approximately 10.3 million shares of our common stock for $837 million, compared with approximately 2.5 million shares of our common stock for $191 million in the prior-year period. Aggregate common stock repurchases are estimated to be approximately $1.5 billion for the full fiscal year 2011. At December 31, 2010, Board authorization to repurchase an additional 18.2 million common shares remained.

As of December 31, 2010, total debt of $2.7 billion represented 35.7% of total capital (shareholders’ equity, net non-current deferred income tax liabilities, and debt), versus 23.7% at September 30, 2010. Short-term debt decreased to 9% of total debt at the end of December 31, 2010, from 12% at September 30, 2010. On November 8, 2010, we issued $700 million of 10-year 3.25% notes and $300 million of 30-year 5.00% notes. The net proceeds from these issuances are expected to be used for general corporate purposes, which may include funding for working capital, capital expenditures, repurchases of our common stock and acquisitions.

We have in place a commercial paper borrowing program that is available to meet our short-term financing needs, including working capital requirements. Borrowings outstanding under this program were $200 million at December 31, 2010. We have available a $1 billion syndicated credit facility with an expiration date in December 2012. This credit facility, under which there were no borrowings outstanding at December 31, 2010, provides backup support for our commercial paper program and can also be used for other general corporate purposes. This credit facility includes a single financial covenant that requires BD to maintain an interest expense coverage ratio (ratio of earnings before income taxes, depreciation and amortization to interest expense) of not less than 5-to-1 for the most recent four consecutive fiscal quarters. On the last eight measurement dates, this ratio has ranged from 26-to-1 to 34-to-1. In addition, we have informal lines of credit outside the United States.

#### Government Receivables

Accounts receivable balances include sales to government-owned or government-supported healthcare facilities. Because these customers are government-owned or supported, we could be impacted by declines in sovereign credit ratings or by defaults in these countries. We continually evaluate all government receivables, particularly in Greece, Spain, Italy, and other parts of Western Europe, for potential collection risks associated with the availability of government funding and reimbursement practices.

In particular, we have experienced significant payment delays in Greece due to the government’s current liquidity issues that have affected its ability to process payments to suppliers within Greece’s national healthcare system. During the fourth quarter of fiscal year 2010, BD accepted a settlement agreement established by Greece’s government to repay all debts associated with its public hospitals’ suppliers incurred since 2005. Under the plan, suppliers will receive cash for debts incurred from 2005 through 2006 and zero-coupon bonds for debts incurred from 2007 through 2009. We believe the current reserves related to such sales are adequate and this concentration of credit risk is not expected to have a material adverse impact on our financial position or liquidity.

#### Cautionary Statement Regarding Forward-Looking Statements

BD and its representatives may from time to time make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases, and our reports to shareholders. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, regulatory approvals, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future — including statements relating to volume growth, sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results — are forward-looking statements.

Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, we undertake no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events and developments or otherwise, except as required by applicable law or regulations.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements. For further discussion of certain of these factors, see Item IA. Risk factors in our 2010 Annual Report on Form 10-K.

- The current conditions in the global economy and financial markets, and the potential adverse effect on the cost of operating our business, the demand for our products and services (particularly in countries where governments are the primary payers of healthcare expenses and research), or our ability to produce our products, including the impact on developing countries. Also, the increase in sovereign debt during the financial crisis as a result of governmental intervention in the world economy poses additional risks to the global financial system and economic recovery. We also sell to government-owned or government-supported healthcare facilities, and any adverse change in the availability of government funding in these countries, particularly in Western Europe, could create potential collection risks associated with such sales.
- The consequences of the recently-enacted healthcare reform legislation in the United States, which implemented an excise tax on U.S. sales of certain medical devices, and which could result in reduced demand for our products, increased pricing pressures or otherwise adversely affect BD’s business.
- Changes in domestic and foreign healthcare industry practices that result in a reduction in procedures using our products or increased pricing pressures, including the continued consolidation among healthcare providers and trends toward managed care and healthcare cost containment (including changes in reimbursement practices by third party payors).
- Regional, national and foreign economic factors, including inflation, deflation, and fluctuations in interest rates and, in particular, foreign currency exchange rates, and the potential effect on our revenues, expenses, margins and credit ratings.
- New or changing laws and regulations affecting our domestic and foreign operations, or changes in enforcement practices, including laws relating to trade, monetary and fiscal policies, taxation (including tax reforms that could adversely impact multinational corporations), sales practices, price controls, licensing and regulatory requirements for new products and products in the postmarketing phase. In particular, the U.S. and other countries may impose new requirements regarding registration, labeling or prohibited materials that may require us to re-register products already on the market or otherwise impact our ability to market our products. Environmental laws, particularly with respect to the emission of greenhouse gases, are also becoming more stringent throughout the world, which may increase our costs of operations or necessitate changes in our manufacturing plants or processes or those of our suppliers, or result in liability to BD.
- Product efficacy or safety concerns regarding our products resulting in product recalls, regulatory action on the part of the U.S. Food and Drug Administration (FDA) or foreign counterparts, declining sales and product liability claims, particularly in light of the current regulatory environment, including increased enforcement activity by the FDA.
- Competitive factors that could adversely affect our operations, including new product introductions (for example, new forms of drug delivery) by our current or future competitors, increased pricing pressure due to the impact of low-cost manufacturers as certain competitors have established manufacturing sites or have contracted with suppliers in low-cost manufacturing locations as a means to lower their costs, patents attained by competitors (particularly as patents on our products expire), and new entrants into our markets.
- The effects of natural disasters, including pandemics, earthquakes, fire, wind or other destructive events, or the effects of climate change on our ability to manufacture our products (particularly where production of a product line is concentrated in one or more plants), or our ability to source materials or components from suppliers that are needed for such manufacturing.
- Fluctuations in the cost and availability of oil-based resins and other raw materials, as well as certain sub-assemblies and finished goods, the ability to maintain favorable supplier arrangements and relationships (particularly with respect to sole-source suppliers), and the potential adverse effects of any disruption in the availability of such items.
- Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, complete clinical trials, obtain regulatory approvals in the United States and abroad, obtain coverage and adequate reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of infringement claims by competitors with respect to patents or other intellectual property rights, all of which can preclude or delay commercialization of a product.
- Fluctuations in the demand for products we sell to pharmaceutical companies that are used to manufacture, or are sold with, the products of such companies, as a result of funding constraints, consolidation or otherwise.
- Fluctuations in U.S. and international governmental funding and policies for life sciences research.
- Our ability to achieve our projected level or mix of product sales. Our earnings forecasts are generated based on projected volumes and sales of many product types, some of which are more profitable than others.
- Our ability to implement our ongoing upgrade of our enterprise resource planning system, as any delays or deficiencies in the design and implementation of our upgrade could adversely affect our business.
- Pending and potential future litigation or other proceedings adverse to BD, including antitrust claims, product liability claims, patent infringement claims, and the availability or collectibility of insurance relating to any such claims.
- The effect of adverse media exposure or other publicity regarding BD’s business or operations, including the effect on BD’s reputation or demand for its products.
- The effects, if any, of governmental and media activities regarding the business practices of group purchasing organizations, which negotiate product prices on behalf of their member hospitals with BD and other suppliers.
- The effect of market fluctuations on the value of assets in BD’s pension plans and to actuarial interest rate and asset return assumptions, which could require BD to make additional contributions to the plans or increase our pension plan expense.
- Political conditions in international markets, including civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders and expropriation of assets by a government, particularly in light of the recent civil unrest in parts of the Middle East.
- Our ability to penetrate developing and emerging markets, which also depends on economic and political conditions, and how well we are able to acquire or form strategic business alliances with local companies and make necessary infrastructure enhancements to production facilities, distribution networks, sales equipment and technology.
- The effects, if any, of future healthcare reform in the countries in which we do business, including changes in government pricing and reimbursement policies or other cost containment reforms.
- The impact of business combinations, including any volatility in earnings relating to acquired in-process research and development assets, and our ability to successfully integrate any business we may acquire.
- Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.
- Issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission.

The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties.

## Controls and procedures

As filed, 1,027 characters.

An evaluation was carried out by BD’s management, with the participation of BD’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BD’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of December 31, 2010. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were, as of the end of the period covered by this report, effective and designed to ensure that material information relating to BD and its consolidated subsidiaries would be made known to them by others within these entities. There were no changes in our internal control over financial reporting during the fiscal quarter ended December 31, 2010 identified in connection with the above referenced evaluation that have materially affected, or are reasonably likely to materially affect, BD’s internal control over financial reporting.

## Risk factors

As filed, 147 characters.

There have been no material changes from the risk factors disclosed in Part 1, Item 1A, of our Annual Report on Form 10-K for the 2010 fiscal year.

Filed Feb 8, 2011.
Source: SEC EDGAR, the filing index for accession 0000950123-11-010361. Last ingested by Listed: Nov 11, 2026, 03:43 ET. No prices; not investment advice.
